Literature DB >> 8177629

Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children.

E G Chadwick1, G Chang, M D Decker, R Yogev, D Dimichele, K M Edwards.   

Abstract

We compared the serologic response of 46 human immunodeficiency virus (HIV)-infected children and adolescents and 61 age-matched controls to standard trivalent inactivated influenza vaccine (A/Taiwan (H1N1), A/Shanghai (H3N2), B/Yamagata). Children were immunized according to the package insert recommendations before the 1990 to 1991 influenza season. Serum antibody titers to influenza A were determined before and 1 month after each vaccination and compared for study and control subjects. Serologic responses of HIV-infected participants were correlated with absolute CD4 counts and stage of HIV disease. Regardless of age or HIV status, all groups responded with significant increases in antibody to the influenza A strains (range, 2.1-fold to 11.8-fold), with the exception that antibody to H3N2 rose only 1.5-fold (P = 0.058) among HIV-positive subjects > or = 9 years old. Pre- and postimmunization antibody titers were significantly higher for controls than for HIV-positive subjects. There was no correlation between serologic responses and CD4 counts among HIV-infected subjects, but those with Centers for Disease Control and Prevention-defined acquired immunodeficiency syndrome responded significantly less well to vaccine. We conclude that HIV-infected children and adolescents produce significant antibody rises after inactivated influenza A vaccination but that their absolute antibody concentrations are lower than those seen in age-matched controls.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8177629     DOI: 10.1097/00006454-199403000-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  17 in total

1.  Response to influenza virus vaccination in vertical HIV infection.

Authors:  E G Lyall; A Charlett; P Watkins; M Zambon
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

2.  Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.

Authors:  Anne B Kristensen; William N Lay; Fernanda Ana-Sosa-Batiz; Hillary A Vanderven; Vijaya Madhavi; Karen L Laurie; Louise Carolan; Bruce D Wines; Mark Hogarth; Adam K Wheatley; Stephen J Kent
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Impact of aging and HIV infection on serologic response to seasonal influenza vaccination.

Authors:  Suresh Pallikkuth; Lesley R De Armas; Rajendra Pahwa; Stefano Rinaldi; Varghese K George; Celeste M Sanchez; Li Pan; Gordon Dickinson; Allan Rodriguez; Margaret Fischl; Maria Alcaide; Savita Pahwa
Journal:  AIDS       Date:  2018-06-01       Impact factor: 4.177

5.  Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Authors:  Patricia M Flynn; Sharon Nachman; Petronella Muresan; Terence Fenton; Stephen A Spector; Coleen K Cunningham; Robert Pass; Ram Yogev; Sandra Burchett; Barbara Heckman; Anthony Bloom; L Jill Utech; Patricia Anthony; Elizabeth Petzold; Wende Levy; George K Siberry; Ruth Ebiasah; Judi Miller; Edward Handelsman; Adriana Weinberg
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

6.  Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults.

Authors:  Mb Kiberd; C Cooper; Jm Slaunwhite; B Halperin; D Haase; Sa McNeil
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 7.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults.

Authors:  Curtis Cooper; Brian Hutton; Dean Fergusson; Edward Mills; Marina B Klein; Guy Boivin; Scott Halperin
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

9.  Vaccination in HIV-infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.663

10.  Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.

Authors:  Curtis Cooper; Anona Thorne; Marina Klein; Brian Conway; Guy Boivin; David Haase; Stephen Shafran; Wendy Zubyk; Joel Singer; Scott Halperin; Sharon Walmsley
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.